The Effect of Berberis Vulgaris Extract on Transaminase Activities in Non-Alcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disorder in western countries and an important cause of liver cirrhosis, as well as liver failure. Up to now, 20‒40% of the individuals suffer from this disorder and its prevalence is estimated around 5‒30% in Asia. The NAFLD is one of the most prevalent causes for increases in liver enzymes and has a close relationship with obesity, dyslipidemia, hypertension, and type II diabetes. However, no definite treatment has been identified for it yet. OBJECTIVES: The present study aimed to investigate the effect of berberis vulgaris extract in inducing changes in liver enzymes levels. PATIENTS AND METHODS: The present clinical trial was conducted on 80 patients, including 32 males (40%) and 48 females (60%), who were randomly assigned into two groups of case and control. All the patients had ultrasound evidence of lipid accumulation in the liver and increases in liver enzymes. The case group received two capsules (750 mg) containing berberis vulgaris extract every day for 3 months, while the control group was treated with placebo. The weight, liver transaminases levels and lipid profiles of the two groups were assessed before, during, and after the study. RESULTS: In the case group, the mean serum levels of alanine transaminase (ALT) and aspartate transaminase (AST) decreased from 49 to 27.48 and 48.22 to 29.8 u/L, respectively, which was statistically significant compared to the control group (P < 0.001, P < 0.001). In the control group, the mean of ALT and AST decreased from 50.4 to 46.8 and 45.7 to 44.9 u/L, respectively. The difference was not statistically significant. In addition, a significant decrease was observed in weight, triglycerides, and cholesterol, while no significant change was found in fasting blood sugar, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL). CONCLUSIONS: Considering the significant decrease in the liver enzymes, triglycerides and cholesterol after using berberis vulgaris extract, further studies with larger sample sizes will identify the accurate dose as well as duration of consumption for this extract, to recommend in the treatment of patients with NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine
Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., Huo, L., Wang, M., Hong, J., Wu, P., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2404 · Cited by 573
Cited by
Berberine and barberry (Berberis vulgaris): A clinical review
Imenshahidi, M., & Hosseinzadeh, H. (2019) · Phytotherapy Research · doi:10.1002/ptr.6252 · Cited by 368
Berberis Vulgaris and Berberine: An Update Review
Imenshahidi, M., & Hosseinzadeh, H. (2016) · Phytotherapy Research · doi:10.1002/ptr.5693 · Cited by 359
Shamsoddini, A., Sobhani, V., Ghamar Chehreh, M. E., Alavian, S. M., & Zaree, A. (2015) · Hepatitis Monthly · doi:10.5812/hepatmon.31434 · Cited by 126
“, Barcelona, Spain) and through the spectrophotometry method (29).”
MethodZamani, M., Zarei, M., Nikbaf-Shandiz, M., Hosseini, S., Shiraseb, F., & Asbaghi, O. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1013055 · Cited by 28
Liu, D., Zhao, H., Zhang, Y., Hu, J., & Xu, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1572197 · Cited by 24
Metadata
- Authors
- Iloon Kashkooli, R., Najafi, S. S., Sharif, F., Hamedi, A., Hoseini Asl, M. K., Najafi Kalyani, M., & Birjandi, M.
- Venue
- Hepatitis Monthly
- Publisher
- Brieflands
- Published
- 2015-02-05
- Volume
- 15
- Issue
- 2
- Pages
- e25067-e25067
- ISSN
- 1735-143X (ISSN-L)
- 1735-3408
- OpenAlex
- W2120952434
- Cited by
- 51
- References
- 1
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.